CTKB Cytek Biosciences Inc.

Medical Device Company
9.96
+0.06  (+1%)
Previous Close 9.9
Open 10
52 Week Low 7.38
52 Week High 28.7
Market Cap $1,337,758,825
Shares 134,313,135
Float 100,177,675
Enterprise Value $1,093,380,811
Volume 527,683
Av. Daily Volume 1,138,457
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Piper Sandler Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/16/2022
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/13/2022
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/12/2022
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/13/2022

Latest News

  1. FREMONT, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB) today reported financial results for the first quarter ended March 31, 2022.

    Recent Highlights

    • Total revenue was $35.1 million for the first quarter, representing a 44% increase over the corresponding quarter of 2021
    • Expanded the installed base to 1,226 instruments, with 116 instrument placements during the first quarter
    • Continued to see demand across the increasingly diversified portfolio of Cytek's offerings, including service revenue that has more than doubled from the prior year

    "I am pleased with our start to the year, with first quarter revenue growing 44% from the prior year," said Dr. Wenbin Jiang, CEO of…

    View Full Article
  2. FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

    Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com

    About Cytek Biosciences
    Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and…

    View Full Article
View All Cytek Biosciences Inc. News